Chronic Kidney DiseasesNCT04714918
Chinese CKD-MBD Prevalence Survey (CRISS-MBD)
An observational study of Chronic Kidney Diseases and Chronic Kidney Disease-Mineral and Bone Disorder, run by Limeng Chen at 40 sites in China.
Trial summary
This is a multi-center cross sectional epidemiological study. The purpose of this study is to investigate the prevalence of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in Chinese population. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder
- How many people
- 10,254 participants
- Where
- 40 sitesChina
- Study dates
- 29 Nov 2020to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: This study plans to include hospitalized CKD patients who are not on dialysis and dialysis patients followed regularly in HD centers or PD centers.
Who may be able to join
- Kidney damage for ≥ 3 months, and one of the following criteria:
- Glomerular filtration rate (GFR) <60 mL/min/1.73m2 for 3 months or more, irrespective of cause.
- proteinuria (>30 mg of urinary albumin excretion per gram of urinary creatinine, > 50 mg of urinary protein excretion per gram of urinary creatinine, >1+ for proteinuria in dipstick, > 0.3g of 24 hour urine protein)
- structural renal abnormalities
- hospitalized patients not on dialysis or dialysis patients followed regularly in Hemodialysis centers or Peritoneal Dialysis centers
Who cannot join
- no available test results within 3 months prior to this study
- no available information of medication or past medical history
Trial locations and contacts
40 sites in 1 country.
40 sites in 1 country
China40 sites, 40 recruiting
- Recruiting
Anshan Central Hospital, Lishan District
Anshan, Liaoning, 114000
Cong Ma, BM, +86-13050031079, macong307@sina.com
Ruiting Lv, BM, +86-13887921956, 273387890@qq.com
- Recruiting
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070
Jing Liu, MD, +86-18910390108, proprock@126.com
Yin Zhang, PhD, +86-15801438634, Zhangyin1228@163.com
- Recruiting
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, 100730
Guojuan Zhang, MD, +86-10-58268488, guojuanzhang@163.com
Kangkang Song, MD, +86-10-58268478, songkangkang0122@sina.com
- Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730
Peng Xia, MD, +86-1381168403, 7-xp@163.com
Xiaohong Fan, MD, +86-13811559757, fxhcmu@163.com
- Recruiting
Beijing Lu-He Hospital, Capital Medical University
Beijing, Beijing Municipality, 101149
Zhongxin Li, MD, +86-15117969360, 13621211613@139.com
Chunxia Shi, MM, +86-18701377094, 422601904@qq.com
- Recruiting
The First Hospital of Fangshan District, Beijing
Beijing, Beijing Municipality, 102400
Xufang Yu, MM, +86-13621246651, yuxufang2@163.com
Xin Jiang, BM, +86-13261156110, 1029379965@qq.com
- Recruiting
Beijing Daxing District People's Hospital
Beijing, Beijing Municipality, 102600
Peiyi Zhou, M.D., +86-13240985938, pyzhou81@163.com
Peiyi Zhou, M.D.
- Recruiting
Benxi Steel General Hospital of Liaoning Health Industry Group
Benxi, Liaoning, 117000
Jia Liu, MM, +86-13274255531, 978470568@qq.com
Wei Wei, MM, +86-18041440516, 974859394@qq.com
- Recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, 410008
Cuifang Li, MM, 15274987725, 810314451@qq.com
Hui Xu, MD
- Recruiting
The First Affiliated Hospital, Chongqing Medical University
Chongqing, Chongqing Municipality, 400016
Enhao Yang, MD, PhD, +86-13983836679, 379239336@qq.com
Wen Wen, MSc, +86-15683168986, 86140771@qq.com
- Recruiting
Chongqing Hospital of Traditional Chinese Medicine
Chongqing, Chongqing Municipality, 400021
Weijian Xiong, BM, +86-13628371818, xwj950806@126.com
Ling Zhang, BM, +86-13370768750, 1648770473@qq.com
- Recruiting
The Ninth People's Hospital of Chongqing
Chongqing, Chongqing Municipality, 400700
Yuanjiang Liao, MM, +86-13272911037, lyj730225@163.com
Yan Shi, MM, +86-13594161996, cqyuxiaoke@163.com
- Recruiting
The Third Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 401120
Shuyu Gong, MM, +86-17380549355, 997283452@qq.com
Jurong Yang, MD, +86-15802391006, 15802391006@163.com
- Recruiting
People's Hospital of Liangping District, Chongqing
Chongqing, Chongqing Municipality, 405200
Hongwen Zhou, MM, +86-13668488428, 910741512@qq.com
Dongju Liu, BM, +86-13628460275, imagiczhou@163.com
- Recruiting
The People's Hospital of Fengdu County
Chongqing, Chongqing Municipality, 408200
Chenghui Tao, BM, +86-13509466553, 542505613@qq.com
Yang Liu, +86-18372552345
- Recruiting
The People's Hospital of Nanchuan District, Chongqing
Chongqing, Chongqing Municipality, 408400
Jie Huo, BM, +86-13896624493, 3127075673@qq.com
You Zhang, BM, +86-17323940871, 1464307302@qq.com
- Recruiting
Dalian University Affiliated Xinhua Hospital
Dalian, Liaoning, 116001
Lin Wang, MM, +86-13940804711, wanglinxinhua@126.com
Qiangqiang Liu, MM, +86-13591717165, liuqiang0720@163.com
- Recruiting
Shunde Hospital of Southern Medical University, The first People's Hospital of Shunde
Foshan, Guangdong, 528300
Xianrui Dou, MD, +86-18825438838, betty9911@163.com
Jianyi Pan, MM, +86-13929129228, 61962030@qq.com
- Recruiting
Fujian Provincial Hospital
Fuzhou, Fujian, 350001
Weihua Liu, MM, 13599394882, 305855638@qq.com
Miao Lin, MD, 13506993517, 10151246@qq.com
- Recruiting
Panyu Central Hospital
Guangzhou, Guangdong, 511400
Rongjun Liu, MD, +86-15920596895, liuerita85@163.com
Jieping Feng, MM, +86-13928786003, Fengjieping090206@126.com
- Recruiting
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 520120
Qiongqiong Yang, MD, +86-13826204650, yangqq@mail.sysu.edu.cn
Rong Huang, MD, +86-18825135993, huangr93@mail.sysu.edu.cn
- Recruiting
Traditional Chinese Hospital of Guyuan
Guyuan, Ningxia, 756000
Shiqiang Shi, BM, +86-13995049152, 290557010@qq.com
Wei Ma, BM, +86-15209676228, 290557010@qq.com
- Recruiting
People's Hospital of Longde County
Guyuan, Ningxia, 756300
Kangzhong Zhang, BM, +86-18095402511, 351600801@qq.com
Lang Luo, BM, +86-18295687489, 810830016@qq.com
- Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000
Lijun Mou, MD, PhD, +86-13757164624, tiantangmou@126.com
Lijun Mou, MD, PhD
- Recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021
Yunhua Liao, MM, +86-13878889238, 993237105@qq.com
Zhenhua Yang, MD, +86-13978806396, 593456108@qq.com
- Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, 110001
Xinwang Zhu, MD, PhD, +86-13804056472, zhuxinwang_cmu@126.com
Li Yao, MD, PhD
- Recruiting
The Seventh Affiliated Hospital, Sun Yat-sen University
Shenzhen, Guangdong, 518000
Zhihua Zheng, MD, +86-13922298682, zhihuazheng@126.com
Ting Zhu, PhD, +86-15521189331, ztzoe_093@163.com
- Recruiting
The People's Hospital of Longhua, The Affiliated Hospital of Southern Medical University
Shenzhen, Guangdong, 518109
Mingliang Hu, MD, +86-15112555656, hubright@foxmail.com
Liting Xu, MM, +86-15625043662, 2423377940@qq.com
- Recruiting
The Fifth People's Hospital of Ningxia Hui Autonomous Region
Shizuishan, Ningxia, 753000
Fengxia Wang, MM, +86-13139529067, wangfengxia1232006@126.com
Yupu Dou, MM, +86-13619516696, douyupudyp@163.com
- Not yet recruiting
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, 830001
Xueqin Zhang, MM, +86-15899197875, 806593091@qq.com
Jing Zhuang, MM, +86-13659928280, 2098602833@qq.com
- Recruiting
People's Hospital of Wuzhong
Wuzhong, Ningxia, 751100
Hongyan Yan, MM, +86-13009722115, zwn080504@163.com
Xiaoxia Luo, MM, +86-18795017564, 1260432244@qq.com
- Recruiting
People's Hospital of Tongxin County
Wuzhong, Ningxia, 751300
Weiquan Zhang, BM, +86-13995454338, 1207829520@qq.com
Lingyan Ma, BM, +86-14760536533, 850862838@qq.com
- Recruiting
People's Hospital of Yanchi County
Wuzhong, Ningxia, 751500
Zhiwen Zhang, BM, +86-13909534706, ywkzzw@163.com
Zhiwen Zhang, BM
- Recruiting
People's Hospital of Yuanzhou District
Wuzhong, Ningxia, 756000
Lili Ao, BM, +86-13389547533, sea.ao@163.com
Bo Lu, BM, +86-15009648668
- Recruiting
Zhongshan Hospital Affiliated to Xiamen University
Xiamen, Fujian, 361000
Xiaodan Guo, MM, +86-15880272062, guoxiaodanzz@163.com
Tianjun Guan, MD, +86-13950199068, guantianjun@aliyun.com
- Recruiting
Ningxia Chinese Medicine Research Center
Yinchuan, Ningxia, 750001
Jinhong Lu, BM, +86-13995116661, Lujinhong0608@126.com
Jiaxiu Li, MM, +86-18298348565, 1054100560@qq.com
- Recruiting
People's Hospital of Ningxia Hui Autonomous Region
Yinchuan, Ningxia, 750001
Yali Zheng, MD, +86-13639505291, 424570556@qq.com
Li Cao, MM, +86-18298348565, 1054100560@qq.com
- Recruiting
The First People's Hospital of Yinchuan
Yinchuan, Ningxia, 750001
Peng Zhang, BM, +86-13995412502, Zhangpeng990212@163.com
Liyuan Ma, MM, +86-13619519668, 1135550734@qq.com
- Recruiting
Third People's Hospital of Yiyang
Yiyang, Hunan, 413000
Xiaoyan Hong, BM, +86-13617376578, 452688345@qq.com
Sha Li, BM, +86-13487801219, 695133217@qq.com
- Recruiting
Zhangzhou People's Hospital
Zhangzhou, Fujian, 363099
Pengfei Huang, BM, +86-18750747718, 552302627@qq.com
Rui Wu, BM
About this study
Official title: Chinese Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Prevalence Survey
This is a multi-center cross sectional epidemiological study. The purpose of this study is to investigate the prevalence of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in Chinese population.
Read the detailed description
The prevalence of Chronic Kidney Disease (CKD) in Chinese population is over 10% and increasing rapidly. Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a constellation of conditions secondary to CKD, including 1) metabolic disorders of calcium, phosphorus and Parathyroid Hormone (PTH), 2) bone diseases and 3) calcifications in blood vessels and soft tissues. CKD-MBD could increase the risks of cardiovascular diseases and bone fracture and overall mortality. However, the data of prevalence of CKD-MBD in Chinese population with different CKD stages is lacking. This is a multi-center cross sectional epidemiological study. The purpose of this study is to investigate the prevalence of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in Chinese population.This is a multi-center cross sectional epidemiological study. The purpose of this study is to investigate the prevalence of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in Chinese population. A questionnaire was designed to collect the information of demographic data, medical history, laboratory test results and medications from the patients. Multistage stratified cluster sampling method will be used. Based on the sample size estimation, a total of 14-28 tertiary hospitals and 42-56 level II hospitals distributed in seven different geographic regions across China will be included. At least 9863 subjects will be enrolled. The primary outcome is the prevalence of CKD-MBD, including the prevalence of hypocalcemia, hyperphosphatemia and secondary hyperparathyroidism.
- Keywords
- Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder, Hypocalcemia, Hyperphosphatemia, Secondary Hyperparathyroidism
- Medical subject headings
- Renal Insufficiency, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder, Hypocalcemia, Hyperphosphatemia, Hyperparathyroidism, Secondary
What is being measured
The primary outcome is the main question the study is designed to answer.
The prevalence of hyperphosphatemia
The prevalence of hyperphosphatemia (serum phosphate > 1.45mmol/L) in the whole study population and in participants with different CKD stages.
Measured: At the end of the enrollment.
Secondary outcomes (5)
The prevalence of hypocalcemia
The prevalence of hypocalcemia (serum calcium < 2.13mmol/L) in the whole study population and in participants with different CKD stages.
Measured: At the end of the enrollment.
The prevalence of secondary hyperparathyroidism
The prevalence of secondary hyperparathyroidism (iPTH > 300pg/ml) in the whole study population and in participants with different CKD stages.
Measured: At the end of the enrollment.
The prevalence of hypercalcemia
The prevalence of hypercalcemia (serum calcium > 2.70mmol/L) in the whole study population and in participants with different CKD stages.
Measured: At the end of the enrollment.
The prevalence of bone fracture
The prevalence of bone fracture in the whole study population and in participants with different CKD stages.
Measured: At the end of the enrollment.
The prevalence of vascular calcification
The prevalence of vascular calcification identified by CT scan or ultrasound in the whole study population and in participants with different CKD stages.
Measured: At the end of the enrollment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2021
- Study start29 Nov 2020
- Primary completion31 Dec 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Chronic Kidney DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 10,254 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Limeng Chen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Limeng Chen, Peking Union Medical College Hospital
- Investigators
- Limeng Chen, MD, PhD, Principal investigator, Peking Union Medical College Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04714918
- Sponsor's protocol ID
- CRISS-MBD
- Status last verified
- Apr 2024
- First submitted
- 14 Jan 2021
- Last updated
- 10 Apr 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: To comply with laws in China, local regulations and hospital policy, IPD sharing might be restricted.
Publications
Zhou C, Wang F, Wang JW, Zhang LX, Zhao MH. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease. Chin Med J (Engl). 2016 Oct 5;129(19):2275-80. doi: 10.4103/0366-6999.190678.
PubMed 27647184Kong X, Zhang L, Zhang L, Chen N, Gu Y, Yu X, Liu W, Chen J, Peng L, Yuan W, Wu H, Chen W, Fan M, He L, Ding F, Chen X, Xiong Z, Zhang J, Jia Q, Shi W, Xing C, Tang X, Hou F, Shu G, Mei C, Wang L, Xu D, Ni Z, Zuo L, Wang M, Wang H. Mineral and bone disorder in Chinese dialysis patients: a multicenter study. BMC Nephrol. 2012 Sep 21;13:116. doi: 10.1186/1471-2369-13-116.
PubMed 22994525
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chinese Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Prevalence Survey
- ClinicalTrials.gov ID
- NCT04714918
- Acronym / sponsor ID
- CRISS-MBD
- Keywords
- Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder, Hypocalcemia, Hyperphosphatemia, Secondary Hyperparathyroidism
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10,254 participants (estimated)
- Lead sponsor
- Limeng ChenUniversity, hospital or other
- Study start
- 29 Nov 2020 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 20 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-center cross sectional epidemiological study. The purpose of this study is to investigate the prevalence of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in Chinese population.
Detailed description
The prevalence of Chronic Kidney Disease (CKD) in Chinese population is over 10% and increasing rapidly. Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a constellation of conditions secondary to CKD, including 1) metabolic disorders of calcium, phosphorus and Parathyroid Hormone (PTH), 2) bone diseases and 3) calcifications in blood vessels and soft tissues. CKD-MBD could increase the risks of cardiovascular diseases and bone fracture and overall mortality. However, the data of prevalence of CKD-MBD in Chinese population with different CKD stages is lacking. This is a multi-center cross sectional epidemiological study. The purpose of this study is to investigate the prevalence of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in Chinese population.This is a multi-center cross sectional epidemiological study. The purpose of this study is to investigate the prevalence of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in Chinese population. A questionnaire was designed to collect the information of demographic data, medical history, laboratory test results and medications from the patients. Multistage stratified cluster sampling method will be used. Based on the sample size estimation, a total of 14-28 tertiary hospitals and 42-56 level II hospitals distributed in seven different geographic regions across China will be included. At least 9863 subjects will be enrolled. The primary outcome is the prevalence of CKD-MBD, including the prevalence of hypocalcemia, hyperphosphatemia and secondary hyperparathyroidism.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This study plans to include hospitalized CKD patients who are not on dialysis and dialysis patients followed regularly in HD centers or PD centers.
Key inclusion criteria (5 listed)
- Kidney damage for ≥ 3 months, and one of the following criteria:
- hospitalized patients not on dialysis or dialysis patients followed regularly in Hemodialysis centers or Peritoneal Dialysis centers
Key exclusion criteria (2 listed)
- no available test results within 3 months prior to this study
- no available information of medication or past medical history
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The prevalence of hyperphosphatemia
Time frame: At the end of the enrollment.
The prevalence of hyperphosphatemia (serum phosphate > 1.45mmol/L) in the whole study population and in participants with different CKD stages.
5 secondary outcomes
The prevalence of hypocalcemia
Time frame: At the end of the enrollment.
The prevalence of secondary hyperparathyroidism
Time frame: At the end of the enrollment.
The prevalence of hypercalcemia
Time frame: At the end of the enrollment.
The prevalence of bone fracture
Time frame: At the end of the enrollment.
The prevalence of vascular calcification
Time frame: At the end of the enrollment.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2024.
- Results publication: PubMed 27647184Zhou C, Wang F, Wang JW, Zhang LX, Zhao MH. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease. Chin Med J (Engl). 2016 Oct 5;129(19):2275-80. doi: 10.4103/0366-6999.190678.
- Results publication: PubMed 22994525Kong X, Zhang L, Zhang L, Chen N, Gu Y, Yu X, Liu W, Chen J, Peng L, Yuan W, Wu H, Chen W, Fan M, He L, Ding F, Chen X, Xiong Z, Zhang J, Jia Q, Shi W, Xing C, Tang X, Hou F, Shu G, Mei C, Wang L, Xu D, Ni Z, Zuo L, Wang M, Wang H. Mineral and bone disorder in Chinese dialysis patients: a multicenter study. BMC Nephrol. 2012 Sep 21;13:116. doi: 10.1186/1471-2369-13-116.
- Individual participant dataSharing planned: No. To comply with laws in China, local regulations and hospital policy, IPD sharing might be restricted.
Related trials for Chronic Kidney Diseases
RecruitingObservational study
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
Chronic Kidney Disease
Active, not recruitingObservational study
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
Chronic Kidney Disease, Type 2 Diabetes Mellitus
RecruitingObservational study
Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation
Cardiovascular Diseases, Kidney Transplant; Complications
Not yet recruiting
Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis
Intradialytic Nausea and Vomiting, Chronic Kidney Disease
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
Chronic Kidney Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Limeng Chen, MD, PhD principal investigator
Peking Union Medical College Hospital
40 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Kidney Diseases and Chronic Kidney Disease-Mineral and Bone Disorder, run by Limeng Chen at 40 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 40 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Peng Xia, MD (+86-13811684903, 7-xp@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The prevalence of hyperphosphatemia (time frame: At the end of the enrollment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04714918, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2024.